Clinical Trial Update: Phase I Single-blind Clinical Trial to Evaluate the Safety and Local Immune Activation of a Toll-like Receptor 5 Agonist (FLAMOD) Administered by Aerosol [Phase 1]

View source ↗

Summary

Phase I trial assessing safety and local immune activation of the TLR5 agonist FLAMOD delivered by aerosol in pneumonia; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia

Drugs mentioned

• FLAMOD

Snippet

Sponsor: Institut National de la Santé Et de la Recherche Médicale, France | Conditions: Pneumonia | Phase 1 | Status: COMPLETED